SCHENECTADY, NY – August 2, 2018 – SI Group, a leading global developer and manufacturer of performance additives and intermediates announced plans today to expand ibuprofen capacity in its Orangeburg, South Carolina facility in the United States. The expansion will increase production by 25% and is expected to commercialize in 2020. This expansion follows a 10% increase that took place in 2018 at the same facility.
“Global megatrends such as population growth, aging demographics and increasing healthcare spending drive the need for affordable analgesics such as ibuprofen,” said Frank Bozich, President & CEO of SI Group. “Our Orangeburg, South Carolina facility has deep expertise in the manufacturing of ibuprofen, and is extremely well positioned to support the significant global growth projected for this product.”
SI Group is a privately-owned performance additives, intermediates and API manufacturer offering a broad array of value-added and niche products that sell into a diverse set of markets. The company’s Orangeburg facility specializes in the production of ibuprofen and propofol for the pharmaceutical market as well as antioxidants products for the plastics and lubricant market. As a recognized leader in ibuprofen, SI Group further strengthens its position in the global marketplace through this expansion.
ABOUT SI GROUP
SI Group is a leading global developer and manufacturer of chemical intermediates, specialty resins, and solutions that are critical to the quality and performance of countless industrial and consumer goods. Founded in 1906 and headquartered in Schenectady, New York, SI Group is a family-owned company with over 2,800 employees worldwide. SI Group operates 20 manufacturing facilities on five continents with over $1 billion in annual sales. In 2017, SI Group received its second silver award for corporate social responsibility by EcoVadis, and is ranked among the top 10 percent of more than 30,000 worldwide companies. SI Group is The Substance Inside. For more information, visit www.siigroup.com.
# # #